Susan Gunn, MD
Pulmonary Disease · New Orleans, LANPI 1134345986
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.7%), education and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 92.8% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $13,197 and has fallen 67.8% since, to $4,252 in 2025. Among pulmonary disease clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 57 payments — averaging $486.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$26K
- Pulmonx Corporation$1K
- AstraZeneca$249
- Johnson & Johnson$160
- GSK$125
- Insmed, Inc.$106
- plus $49 from 2 others
What the payments were for
- Speaking & faculty fees$16,00058%
- Travel & lodging$4,48116%
- Food & beverage$2,74210%
- Education$4,50016%
- Gifts$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 44 | $25,750 |
| Pulmonx Corporation | 3 | $1,297 |
| AstraZeneca | 2 | $249 |
| Johnson & Johnson | 3 | $160 |
| GSK | 1 | $125 |
| Insmed, Inc. | 1 | $106 |
| Olympus America Inc. | 2 | $29 |
| Genentech USA, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$25,148
- Pulmonx Endobronchial Valve EBV$1,237
- BREZTRI AEROSPHERE$126
- ANORO$125
- FASENRA$123
- Monarch Platform$116
- Arikayce$106
How this compares
$27,737 in reported general payments places this provider in the 95th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 12 | $155,958 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $55,444 |
| Spiriva RespimatTiotropium Bromide | 53 | $32,322 |
| Spiriva HandihalerTiotropium Bromide | 27 | $22,013 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 34 | $16,180 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $14,704 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $10,948 |
| Incruse ElliptaUmeclidinium Bromide | 22 | $8,943 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $8,526 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $5,204 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 32 | $4,982 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 127 | $3,469 |
| Azithromycin | 65 | $482 |
| Fluticasone Propionate | 15 | $319 |
| Cyproheptadine Hcl | 12 | $204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $125 | $90,039142 claims |
| AstraZenecaBevespi Aerosphere, Symbicort | $249 | $21,38455 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 189 pulmonary disease providers in Louisiana.
Other pulmonary disease in New Orleans
- Joseph LaskyNew Orleans$447K
- Ramsy AbdelghaniNew Orleans$308K
- Juzar AliNew Orleans$216K
- Nicole LapinelNew Orleans$140K
- Courtney ShappleyNew Orleans$66K
- David PattenNew Orleans$12K
- Yasin KhanNew Orleans$12K
- Ross KlingsbergNew Orleans$11K
- Nereida ParadaNew Orleans$10K
- Leonard GladeNew Orleans$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.